Glenview Trust co Sells 57,982 Shares of Edwards Lifesciences Co. (NYSE:EW)

Glenview Trust co lowered its holdings in Edwards Lifesciences Co. (NYSE:EW) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 357,562 shares of the medical research company’s stock after selling 57,982 shares during the period. Glenview Trust co owned approximately 0.06% of Edwards Lifesciences worth $26,470,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares during the last quarter. Geode Capital Management LLC grew its position in Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Fisher Asset Management LLC increased its stake in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after acquiring an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $555,939,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,803 shares of company stock valued at $3,900,976 in the last three months. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on EW shares. Piper Sandler upped their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Citigroup increased their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Up 2.1 %

EW stock opened at $69.37 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market capitalization of $40.78 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business’s 50 day moving average price is $71.74 and its two-hundred day moving average price is $70.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.